Sulfa Quin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfaquinoxaline is reported as an ingredient of Sulfa Quin in the following countries:
International Drug Name Search
Dilopin may be available in the countries listed below.
Amlodipine is reported as an ingredient of Dilopin in the following countries:
International Drug Name Search
OBAGI-C® RX SYSTEM
WELCOME TO THE OBAGI-C® RX SYSTEM OF SKIN CARE PRODUCTS!
FOR TOPICAL USE ONLY
With Obagi-C Rx, you’re on your way to healthier, refreshed, revitalized skin from cell to surface. Obagi-C Rx Systems promote skin rejuvenation from the inside out using a formulation of prescription-strength hydroquinone USP, 4%, which reduces the appearance of hyperpigmentation and age spots, combined with 10% L-ascorbic acid (Vitamin C)—the only topical antioxidant proven to stimulate collagen synthesis and protect your skin by minimizing future skin cell damage.
Please read this product information prior to use of the Obagi-C Rx System. Any questions regarding your particular skin care regimen should be directed toward your physician or skin care specialist. You can also obtain more information about the Obagi-C Rx System or other Obagi systems by visiting our Web site at www.obagi.com.
FOR EXTERNAL USE ONLY Rx Only
62032-106-10 OBAGI-C RX SYSTEM C-CLARIFYING SERUM FOR NORMAL TO DRY SKIN
Hydroquinone USP, 4%
Ascorbic Acid, Propylene Carbonate, Propylene Glycol, Sodium Lauryl Sulfate, Water
62032-122-10 OBAGI-C RX SYSTEM C-CLARIFYING SERUM FOR NORMAL TO OILY SKIN
Hydroquinone USP, 4%
Ascorbic Acid, Dipropylene Glycol, Ethyl Alcohol, Fragrance, Propylene Carbonate, Propylene Glycol, Sodium Lauryl Sulfate, Water
62032-105-36 OBAGI-C RX SYSTEM C-THERAPY NIGHT CREAM
Hydroquinone USP, 4%
Ascorbic Acid, BHT, Cetyl Alcohol, Disodium EDTA, Glycerin, Lactic Acid, Methylparaben, Phenyl Trimethicone, PPG-2 Myristyl Ether Propionate, Propylparaben, Saponins, Sodium Lauryl Sulfate, Sodium Metabisulfite, TEA-Salicylate, Tocopheryl Acetate, Water
Hydroquinone is 1,4-benzenediol. Hydroquinone occurs as fine, white needles. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C6H6O2; molecular weight is 110.11 g/mol. The chemical structure is in diagram to right.
Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (dopa) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunblocking agents or sunscreen agents contained in the Obagi-C Rx System C-SunGuard SPF 30.
The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.
A thin application should be applied to the affected area twice daily or as directed by a physician. If no improvement is seen after 8‑12 weeks of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent, a sunblocking agent, or protective clothing to cover bleached skin when using and after using this product in order to prevent repigmentation.
(ALSO SEE WARNINGS)
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Safety and effectiveness in children below the age of 12 years have not been established.
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and physician notified immediately.
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
Store at controlled room temperature: 15°-25°C (59°-77°F), and keep out of direct sunlight.
Obagi Medical Products, Inc. Long Beach, CA 90806, U.S.A. www.obagi.com 60501510X Patent #4,983,382; 5,516,793; 5,703,122; 6,299,889 - Rev. 02/10
OBAGI-C®
RX SYSTEM
NDC # 62032-122-10
NON-COMEDOGENIC
NON-ACNEGENIC
C-CLARIFYING SERUM
SKIN LIGHTENING SERUM
WITH VITAMIN C 10%
HYDROQUINONE USP, 4%
RX ONLY
FOR NORMAL TO OILY SKIN
AM
1 FL. OZ. (30 Ml)
| Obagi C Rx System C Clarifying Serum hydroquinone cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| UNAPPROVED DRUG OTHER | 08/31/2010 | ||
| Labeler - Obagi Medical Products, Inc. (790553353) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| PureTek Corporation | 785961046 | LABEL, MANUFACTURE, PACK | |
Eritromicina Etilsuccinato Induquimica may be available in the countries listed below.
Erythromycin ethylsuccinate (a derivative of Erythromycin) is reported as an ingredient of Eritromicina Etilsuccinato Induquimica in the following countries:
International Drug Name Search
